Published in Br J Clin Pharmacol on August 01, 1978
Beta-adrenoceptor blockers and the blood-brian barrier. Br J Clin Pharmacol (1981) 1.60
Absorption and excretion of rapid and slow release oxprenolol and their effects on heart rate and blood pressure during exercise. Br J Clin Pharmacol (1979) 1.59
Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol (1980) 1.55
A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers. Br J Clin Pharmacol (1985) 1.27
The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br J Clin Pharmacol (1983) 1.13
Propranolol LA and ambulatory blood pressure. Br J Clin Pharmacol (1980) 1.07
Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut (1984) 1.00
Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol (1981) 1.00
Lack of significant effect of therapeutic propranolol on measurable platelet function in healthy subjects. J Clin Pathol (1989) 0.88
Clinical experience with once-daily tacrolimus in de novo kidney transplant recipients from living donors in Japan: 1-year follow up. Cent European J Urol (2013) 0.88
A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls. Br J Clin Pharmacol (1987) 0.84
Effect of metoclopramide on the bioavailability of long-acting propranolol. Br J Clin Pharmacol (1981) 0.81
Comparison of the efficacy and acceptability of nicardipine and propranolol, alone and in combination, in mild to moderate hypertension. Br J Clin Pharmacol (1989) 0.81
The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide. Br J Clin Pharmacol (1982) 0.80
The effect of a week's beta-adrenoceptor antagonism on daytime heart-rates, subjective responses to exercise, and physical activity in normal subjects. Br J Clin Pharmacol (1985) 0.80
Concentration-effect relationships for oxprenolol in patients with essential hypertension. Br J Clin Pharmacol (1988) 0.78
Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. Br J Clin Pharmacol (1989) 0.76
Comparison of propranolol and propranolol LA in hypertension using 24-hr noninvasive blood pressure monitoring. Postgrad Med J (1983) 0.75
Anti-hypertensive therapy with propranolol during pregnancy and lactation. Postgrad Med J (1981) 0.75
Comparison of propranolol and inderal L.A. in patients with angina. Ulster Med J (1980) 0.75
Effects of indomethacin and (+/-)-propranolol on the cardiovascular and renin responses to vasoactive intestinal polypeptide (VIP) infusion in man. Br J Clin Pharmacol (1987) 0.75
Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers. Br J Clin Pharmacol (1982) 0.75
Exercise and resting blood pressure and heart rate changes 24 h after dosing in patients with essential hypertension receiving 16/260 oxprenolol Oros once daily. Br J Clin Pharmacol (1985) 0.75
Pre-dosing plasma concentrations and beta-adrenoceptor blocking effects during repeated once daily dosing with 160 mg sustained-release propranolol (Inderal LA) and 16/260 oxprenolol Oros to healthy volunteers. Br J Clin Pharmacol (1985) 0.75
Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations. Br J Clin Pharmacol (1984) 0.75
Plasma propranolol levels in adults with observations in four children. Clin Pharmacol Ther (1970) 9.54
To be taken as directed. J R Coll Gen Pract (1968) 3.54
Propranolol in hypertension: a study of long-term therapy, 1964-1970. Am Heart J (1972) 3.20
The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. J Pharmacol Exp Ther (1973) 2.54
beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol (1976) 2.17
Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation (1975) 1.92
Individualization of propranolol therapy. Med Clin North Am (1974) 1.37
Propranolol given twice daily in hypertension. Acta Med Scand (1973) 1.19
Why are doctors so unhappy? There are probably many causes, some of them deep. BMJ (2001) 22.59
Evidence based medicine. BMJ (1995) 21.24
What clinical information do doctors need? BMJ (1996) 16.23
Three-dimensional structure of myosin subfragment-1: a molecular motor. Science (1993) 14.90
Informed consent: the intricacies. BMJ (1997) 13.97
An ethical code for everybody in health care. BMJ (1998) 9.13
All changed, changed utterly. British medicine will be transformed by the Bristol case. BMJ (1998) 9.08
Growing pressure on BMJ's obituaries. BMJ (1995) 8.92
Authorship: time for a paradigm shift? BMJ (1997) 8.90
Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA (2001) 8.80
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
The failings of NICE. BMJ (2000) 8.50
The future of medicine. BMJ (1994) 8.14
A good death. An important aim for health services and for us all. BMJ (2000) 8.03
Using evidence to inform health policy: case study. BMJ (2001) 7.99
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet (1999) 7.72
Time to face up to research misconduct. BMJ (1996) 7.66
Beyond conflict of interest. Transparency is the key. BMJ (1998) 7.63
Meeting the information needs of health workers in developing countries. BMJ (1997) 6.31
Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science (1997) 6.10
Medicine's core values. BMJ (1994) 5.93
Revel in electronic and paper media. BMJ (2000) 5.82
The GMC on performance. BMJ (1992) 5.57
Informed consent: edging forwards (and backwards) BMJ (1998) 5.52
PubMed Central: creating an Aladdin's cave of ideas. BMJ (2001) 5.49
Does Britain need an academy of medicine? BMJ (1996) 5.47
Effect of open peer review on quality of reviews and on reviewers' recommendations: a randomised trial. BMJ (1999) 5.45
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Rationing: the search for sunlight. BMJ (1992) 5.26
Publishing information about patients. BMJ (1995) 5.19
The future of healthcare systems. BMJ (1997) 5.14
Prejudice against doctors and students from ethnic minorities. Br Med J (Clin Res Ed) (1987) 5.12
The war on drugs. BMJ (1996) 5.11
Global information flow. BMJ (2000) 5.09
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
What makes a good reviewer and a good review for a general medical journal? JAMA (1998) 5.01
A combined PET/CT scanner for clinical oncology. J Nucl Med (2000) 4.99
Where is the wisdom...? BMJ (1991) 4.85
Medicine and the marginalised. They deserve the best, not the poorest, care. BMJ (2000) 4.80
Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol (1996) 4.67
X-ray structures of the myosin motor domain of Dictyostelium discoideum complexed with MgADP.BeFx and MgADP.AlF4-. Biochemistry (1995) 4.64
Time to register randomised trials. The case is now unanswerable. BMJ (1999) 4.55
PFI: perfidious financial idiocy. A "free lunch" that could destroy the NHS. BMJ (1999) 4.54
Moving beyond journals: the future arrives with a crash. BMJ (1999) 4.49
Rationing: the debate we have to have. BMJ (1995) 4.47
Time to redefine authorship. BMJ (1996) 4.39
Complete nucleotide sequence of a milk-transmitted mouse mammary tumor virus: two frameshift suppression events are required for translation of gag and pol. J Virol (1987) 4.37
Animal research: the need for a middle ground. BMJ (2001) 4.34
Conflict of interest and the BMJ. BMJ (1994) 4.34
Prison medicine: beginning again. BMJ (1992) 4.29
Measuring the social impact of research. BMJ (2001) 4.17
The case for structuring the discussion of scientific papers. BMJ (1999) 4.16
Peer review: reform or revolution? BMJ (1997) 4.13
Profile of the GMC: The day of judgment comes closer. BMJ (1989) 4.10
Managing the clinical performance of doctors. A coherent response to an intractable problem. BMJ (1999) 4.08
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut (2004) 4.06
Effect of blinding and unmasking on the quality of peer review: a randomized trial. JAMA (1998) 4.03
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell (1983) 3.89
Protein kinase activity associated with polyoma virus middle T antigen in vitro. Cell (1979) 3.78
Babies sleeping with parents: case-control study of factors influencing the risk of the sudden infant death syndrome. CESDI SUDI research group. BMJ (1999) 3.76
Profile of the GMC. 1978 and all that. BMJ (1989) 3.76
"Taken from this place and hanged by the neck...". BMJ (1991) 3.72
The rights of patients in research. BMJ (1995) 3.68
All doctors are problem doctors. BMJ (1997) 3.67
The BMJ's website scales up. BMJ (1998) 3.67
Publishing research supported by the tobacco industry. BMJ (1996) 3.65
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
How best to organise acute hospital services? BMJ (2001) 3.63
Improving the repeat prescribing process in a busy general practice. A study using continuous quality improvement methodology. Qual Health Care (1999) 3.61
Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell (1984) 3.61
Netprints: the next phase in the evolution of biomedical publishing. BMJ (1999) 3.60
Unbuffered highly acidic gastric juice exists at the gastroesophageal junction after a meal. Gastroenterology (2001) 3.52
GMC: approaching the abyss. BMJ (2001) 3.52
What do we know about how to do audit and feedback? Pitfalls in applying evidence from a systematic review. BMC Health Serv Res (2005) 3.51
The deliberate misdiagnosis of major depression in primary care. Arch Fam Med (1994) 3.46
The Uterine Mucosa in Menstruation and Pregnancy; the Action of the Chorionic Cells and the Function of the Decidua: Structure of the Uterine Mucosa and the Cause of the Opening-up of the Vessels during Menstruation. Proc R Soc Med (1911) 3.46
Pleasing both authors and readers. A combination of short print articles and longer electronic ones may help us do this. BMJ (1999) 3.44
New government, same narrow vision. BMJ (1998) 3.40
Don't treat shackled patients. BMJ (1997) 3.40
Adenocarcinoma of colon differentiating as dome epithelium of gut-associated lymphoid tissue. Histopathology (2000) 3.36
The woolwich and erith project. Planning a community health service. Lancet (1966) 3.34
Almost no evidence exists that the internet harms health. BMJ (2001) 3.31
Characterization of different tumor antigens present in cells transformed by simian virus 40. Cell (1979) 3.26
Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr (1990) 3.24
The estimation of two collagens from human dermis by interrupted gel electrophoresis. Biochem Biophys Res Commun (1976) 3.22
Opening up BMJ peer review. BMJ (1999) 3.21
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Doctors, unethical treatments, and turning a blind eye. BMJ (1989) 3.13
The AEtiology of Eclampsia and Albuminuria and their Relation to Accidental Haemorrhage: (An Anatomical and Experimental Investigation.). Proc R Soc Med (1914) 3.13
Morphology of sporadic colorectal cancer with DNA replication errors. Gut (1998) 3.11
Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst (1999) 3.07
Performance evaluation of the microPET P4: a PET system dedicated to animal imaging. Phys Med Biol (2001) 3.07
Reconfiguring acute hospital services. No easy answers, but there are principles we should follow. BMJ (1999) 3.07
Authorship is dying: long live contributorship. BMJ (1997) 3.07
Hamster health care. BMJ (2001) 3.06
Promoting research into peer review. BMJ (1994) 3.05
Rationing health care: moving the debate forward. BMJ (1996) 3.03
Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics (2001) 3.02